China-based Zhejiang Doer Biologics Co., Ltd has announced a clinical trial collaboration agreement with US major Merck, Sharp & Dohme Inc. (MSD, NYSE: MRK) to investigate Doer Bio’s anti-Claudin18.2 antibody DR30303 in combination with MSD’s anti-PD-1 therapy Keytruda (pembrolizumab) in patients with gastric or gastroesophageal junction cancer (GC/GEJ). Under the agreement, Doer will conduct a clinical study based on a mutually-agreed and finalized protocol to evaluate the safety and efficacy of DR30303 in combination with Keytruda in patients with CLDN18.2-positive, locally advanced unresectable or metastatic GC/GEJ.
DR30303: A Promising Anti-Claudin18.2 Antibody
DR30303 is a humanized anti-CLDN18.2 heavy chain antibody Fc fusion protein (VHH-Fc) generated via Doer Bio’s proprietary SMART-VHHBody platform. The antibody exhibits strong and highly selective binding to CLDN18.2, enhanced antibody-dependent cellular cytotoxicity (ADCC) activity due to Fc engineering, and low immunogenicity risk validated via in-silico T-cell epitope predictor. Preclinical studies have shown promising signs of anti-tumor activity, both alone and in combination with chemotherapies and PD-1 checkpoint blockade, as well as favorable pharmacokinetic properties.
Doer Bio: A Leader in Multi-Specific Biotherapeutics
Doer Bio is a clinical-stage biopharma focused on the development of multi-domain based multi-specific biotherapeutics. The company boasts multiple proprietary platform technologies, including xLONGylation, MultiBody, AccuBody, and SMART-VHHBody, which are designed to enhance the development of innovative and effective treatments for various cancers.-Fineline Info & Tech
